explore -WSS

explore

author：comprehensive 2025-10-04 06:31:49 - browse：62

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Wikipedia

WSS

Cord blood banking comes at a high cost to babies

Millions may soon lose Medicaid when they don't have to

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Inside the rise of 'mukbang' eating videos

How to increase colonoscopy rates? Looks like an AI can help

Canadian wildfire dangers should prompt more proactive mitigation from government: Experts

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

In age of alternative facts, a scholarly course on calling out crap

Letters to First Opinion on caregivers, digital health, and more

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

At ASCO, AstraZeneca reports strong data for breast cancer drug

After affirmative action ruling, medical educators look to 'holistic review'

Novo pauses ads for weight loss drug Wegovy amid demand

Psychedelics group wrestles with new pharma identity

The thinking behind the controversial eating disorder chatbot Tessa

23andMe had bad news about my health. I wish a person had delivered it

Letters to First Opinion on caregivers, digital health, and more

knowledge

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Kaiser's Risant Health gobbled up Geisinger. Who is next?

NIH documents show early flaws of $1.6 billion long Covid program

Sea level rise could wash away turtle breeding grounds around the world, researchers say

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

focus

Wikipedia

knowledge

entertainment